XML 28 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual) - USD ($)
shares in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2015
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Mar. 09, 2011
Currency Hedge Agreement [Member]          
Collateral Already Posted, Aggregate Fair Value   $ 0   $ 0  
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]          
Derivative, Loss on Derivative   2,753,000      
Derivative, Gain on Derivative     $ 464,000    
JPR Royalty Sub LLC [Member]          
Revenue Recognition Royalty and Milestone Revenue Recognized         $ 30,000,000
Debt Issuance Costs Reclassifed from Other Current Assets [Member] | December 31, 2015 [Member]          
Prior Period Reclassification Adjustment   2,196,000      
Royalty Receivable [Member]          
Restricted Cash and Cash Equivalents, Current   562,000      
Collateral for Credit [Member]          
Restricted Cash and Cash Equivalents   $ 1,403,000      
Maximum [Member]          
Maturity Period of High Quality Marketable Securities   3 years      
Average Maturity Period of High Quality Marketable Securities   1 year 180 days      
Maturity Period of Short Term Investment   1 year      
Average Maturity for Portfolio Investments       1 year 180 days  
Minimum [Member]          
Maturity Period of Short Term Investment   90 days      
Long-term Investment Maturity, Minimum   1 year      
Computer Equipment [Member]          
Property, Plant and Equipment, Useful Life   3 years      
Laboratory Equipment, Office Equipment and Software [Member]          
Property, Plant and Equipment, Useful Life   5 years      
Furniture and Fixtures [Member]          
Property, Plant and Equipment, Useful Life   7 years      
Leasehold Improvements [Member] | Birmingham Research Facility [Member]          
Property, Plant and Equipment, Useful Life   20 years 182 days      
Property, Plant and Equipment, Gross   $ 1,589,000      
Lease Financing Obligation, Net of Current   2,506,000      
Agreement [Member] | CSL [Member] | RAPIVABMember | Contingent upon EU Marketing Approval [Member]          
Proceeds from License Fees Received $ 7,000,000        
Agreement [Member] | CSL [Member] | RAPIVABMember | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]          
Deferred Revenue, Additions 3,740,000        
Agreement [Member] | CSL [Member] | RAPIVABMember | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]          
Deferred Revenue, Additions 1,223,000        
Agreement [Member] | CSL [Member] | RAPIVABMember          
Proceeds from License Fees Received 33,740,000        
Revenues 21,777,000        
Milestone Payment Maximum $ 12,000,000        
RAPIVABMember | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member]          
Concentration Risk, Percentage       90.00%  
PhaRMA Notes Member]          
Interest Expense   1,338,000 1,315,000    
Birmingham Research Facility [Member]          
Interest Expense   132,000      
Capital Leases, Future Minimum Payments Due   4,839,000      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   0 8,000    
Amortization of Debt Issuance Costs   110,000 110,000    
Investments and Cash   $ 78,915,000      
Maturity of Investments   3 years      
Restricted Cash and Cash Equivalents, Current   $ 1,965,000   $ 1,612,000  
Revenues   4,820,000 6,826,000    
Interest Expense   1,470,000 $ 1,315,000    
Lease Financing Obligation, Net of Current   $ 2,506,000   $ 2,375,000  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount   1,330 3,529